Nirmatrelvir inhibitor yeSARS-CoV-2 main protease (Mpro), inonziwo 3C-like protease (3CLpro) kana nsp5 protease. Inhibition yeSARS-CoV-2 Mpro inoita kuti isakwanise kugadzirisa mapolyprotein precursors, kudzivirira kudzokororwa kwehutachiona.

Nirmatrelvir yakavharira chiitiko chezve recombinant SARS-CoV-2 Mpro mune biochemical assay pazvimiro zvinogoneka mu vivo. Nirmatrelvir yakawanikwa ichisunga yakananga kuSARS-CoV-2 Mpro inoshanda saiti neX-ray crystallography.

Ritonavir ndeye HIV-1 protease inhibitor asi haishande kurwisa SARS-CoV-2 Mpro. Ritonavir inhibits the CYP3A-mediated metabolism ye nirmatrelvir, zvichiita kuti kuwedzera kweplasma ye nirmatrelvir.

Mushonga uyu unokurudzirwa. Yakapihwa mvumo yekushandiswa kwechimbichimbi neFDA yekurapa zvinyoro-kusvika-zvine mwero coronavirus chirwere (COVID-19) muvakuru uye varwere vevana (makore gumi nemaviri ekuberekwa zvichikwira anorema angangoita makumi mana makirogiramu kana makumi masere nemasere makirogiramu) mhedzisiro yakanaka yeyakananga SARS-CoV-2 kuyedzwa, uye vari panjodzi huru yekufambira mberi kune yakanyanya COVID-19, kusanganisira kuchipatara kana kufa. Nirmatrelvir/ritonavir inofanira kutangwa nekukasika mushure mekuongororwa kweCCIDID-19 uye mukati memazuva mashanu ekutanga kwechiratidzo.

Zvinokurudzirwa zvinobva paEPIC-HR, chirongwa chePhase2/3 randomized Clinical control test kuongorora kushanda kwenirmaltrelivir/ritonavir vs. vanhu vari panjodzi yekuenderera mberi nechirwere chakakomba vakaderedza njodzi yekurara muchipatara kana kufa kuburikidza nemazuva makumi maviri nemasere 88%.